Image Place holder

Hailing Zhang, MD

Specialty: Pathology
Sub Specialty: Pathology-Hematology
Program: Pathology


Cancer Focus: Cutaneous Lymphoma (CTCL), Hodgkin Lymphoma, Leukemia, Multiple Myeloma-Plasma Cell Tumor, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

Hailing Zhang, MD is an Assistant Member in Moffitt’s Department of Hematopathology and Laboratory Medicine and Assistant Professor of Oncologic Sciences at USF. Dr. Hailing Zhang received her Bachelor of Medicine degree from the Medical College of TongJi University in Shanghai, China in 1994 (1989-1994) and completed a renal pathology fellowship in Shanghai Medical University. In 1996, she came to the United States and attended graduate school at the University of Arkansas for Medical Sciences (UAMS) where she received her MS degree in pathology in 1999. She subsequently spent 7 years working (UAMS and Tufts University School of Medicine) as a research associate. She completed her pathology residency training in New Jersey Medical School (UMDNJ-Newark) between 2006 and 2010 and hematopathology fellowship training in Montefiore Medical Center (MMC) in New York. Upon finishing training, she joined Chilton Hospital in New Jersey and served as a staff pathologist before coming to Moffitt Cancer Center in 2012. Dr. Zhang is a dedicated clinician educator whose clinical and research interests include morphologic evaluation, immunophenotyping and molecular diagnosis of hematolymphoid malignancies. As PI or co-investigator on several university or hospital funded projects, she reviews the morphology, immunophenotype, and molecular classification, and develops budgets, compliance oversight and effective measures of analysis. As faculty she is also dedicated to teaching medical students, residents, fellows and international scholars. In addition, she serves as medical director of Specimen Processing, Chair of the Laboratory Safety Committee and Chair of the Committee for Laboratory Diagnostics. Her clinical interests focus on clinical diagnostic hematopathology, including leukemia, lymphoma, clinical flow cytometry and molecular genetics.

Education & Training


  • Shanghai Medical University - Renal Pathology
  • Albert Einstein College of Medicine Montefiore Medical Center - Hematopathology


  • UMDNJ-New Jersey Medical School -

Medical School:

  • TongHi University Medical School - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Song J, Liu K, Pinilla-Ibarz J, Zhang H. A case report and case review: Chronic myeloid leukemia (CML) blast phase with myelomastocytic differentiation. Leuk Res Rep. 2020 Sep.14:100222. Pubmedid: 33072512. Pmcid: PMC7549112.
  • Afiat TP, Zhang X, Zhang H, Ayala E, Zhang L, Sokol L. Sezary syndrome manifesting as posttransplant lymphoproliferative disorder. Leuk Res Rep. 2018 May.9:72-75. Pubmedid: 29761072. Pmcid: PMC5948470.
  • Song J, Hussaini M, Zhang H, Shao H, Qin D, Zhang X, Ma Z, Hussnain Naqvi SM, Zhang L, Moscinski LC. Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. Am J Clin Pathol. 2017 May.147(5):444-452. Pubmedid: 28419183. Pmcid: PMC5402718.
  • Dalia S, Brayer J, Horna P, Zhang H, Pinilla-Ibarz J. Transformation to Hodgkin lymphoma in chronic lymphocytic leukemia coexisting with Epstein-Barr viremia. Leuk Lymphoma. 2014 Nov.55(11):2660-2662. Pubmedid: 24528217.
  • Zhang H, Gupta G, Yang XY, Rosenbluth R, Bhattacharyya PK. A unique case of merkel cell carcinoma and chronic lymphocytic leukaemia presenting in a single cutaneous lesion (collision tumour). BMJ Case Rep. 2011 Nov.2009. Pubmedid: 21686502. Pmcid: PMC3027557.
  • Maitta RW, Wolgast LR, Wang Q, Zhang H, Bhattacharyya P, Gong JZ, Sunkara J, Albanese JM, Pizzolo JG, Cannizzaro LA, Ramesh KH, Ratech H. Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia. Am J Hematol. 2011 Feb.86(2):230-234. Pubmedid: 21264917.
  • Zhang H, Maitta RW, Bhattacharyya PK, Florea AD, Sen F, Wang Q, Ratech H. γ-Synuclein is a promising new marker for staining reactive follicular dendritic cells, follicular dendritic cell sarcoma, Kaposi sarcoma, and benign and malignant vascular tumors. Am J Surg Pathol. 2011 Dec.35(12):1857-1865. Pubmedid: 21959308.
  • Zhang H, Yang XY, Hong T, Feldman T, Bhattacharyya PK. Kaposi sarcoma-associated herpesvirus (human herpesvirus type 8)-associated extracavitary lymphoma: Report of a case in an HIV-positive patient with simultaneous kaposi sarcoma and a review of the literature. Acta Haematol. 2010 Jun.123(4):237-241. Pubmedid: 20484888.
  • Bose C, Zhang H, Udupa KB, Chowdhury P. Activation of p-ERK1/2 by nicotine in pancreatic tumor cell line AR42J: effects on proliferation and secretion. Am J Physiol Gastrointest Liver Physiol. 2005 Nov.289(5):G926-G934. Pubmedid: 16051920.
  • Zhang H, Jia Y, Cooper JJ, Hale T, Zhang Z, Elbein SC. Common variants in glutamine:fructose-6-phosphate amidotransferase 2 (GFPT2) gene are associated with type 2 diabetes, diabetic nephropathy, and increased GFPT2 mRNA levels. J Clin Endocrinol Metab. 2004 Feb.89(2):748-755. Pubmedid: 14764791.
  • Elbein SC, Zheng H, Jia Y, Chu W, Cooper JJ, Hale T, Zhang Z. Molecular screening of the human glutamine-fructose-6-phosphate amidotransferase 1 (GFPT1) gene and association studies with diabetes and diabetic nephropathy. Mol Genet Metab. 2004 Aug.82(4):321-328. Pubmedid: 15308130.
  • Wang H, Zhang H, Jia Y, Zhang Z, Craig R, Wang X, Elbein SC. Adiponectin receptor 1 gene (ADIPOR1) as a candidate for type 2 diabetes and insulin resistance. Diabetes. 2004 Aug.53(8):2132-2136. Pubmedid: 15277397.

Patient Comments
Overall Satisfaction

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments